A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor
This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.
Solid Tumor
BIOLOGICAL: iNK Injection
Adverse Event(AE) ，Serious Adverse Event(SAE)，Treatment Emergent Adverse Event（TEAE）and Treatment Related Adverse Event(TRAE), Number of participants with treatment-related adverse events or serious adverse events as assessed by CTCAE v5.0, From the date of initial infusion to a year after initial infusion|Dose-Limiting Toxicity(DLT), Number of participants with Dose-limiting toxicity in 28 days after injection, 4 weeks after initial infusion
Objective Response Rate（ORR）, Percentage of participants achieved Complete Response(CR) or Partial Response(PR), During the whole study|Disease Control Rate（DCR）, Percentage of participants achieved Complete Response(CR) or Partial Response(PR) or Stable Disease(SD), From the date of initial infusion to a year after initial infusion|Duration Of Response（DOR）, Duration for the first PR to the first Progressive Disease(PD), First Injection to a year after Last Injection
Solid tumor is a disease with high mortality rates. The aim of this trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.